One of the fastest-growing segments of pharmaceuticals, as highlighted at the 2024 J.P. Morgan Healthcare Conference, is the antibody-drug conjugate (ADC) segment. ADCs consist of four main elements: ...

Lonza and Singzyme will use Singzyme’s enzymatic conjugation platform to develop novel bioconjugates. Lonza and Singzyme, a biotechnology company specializing in developing enzymes for protein ...

Lonza entered into two new collaborations with McSAF and Cristal Therapeutics to expand its bioconjugates offering. The collaborations are geared to enable the integration of two novel conjugation ...

Fundamentally, Konkolewicz and Page's technique enables chemists from around the globe to collaborate on the establishment of a set of design rules to guide more rapid development of bioconjugates ...

The market for HPAPIs is growing rapidly with the research industry's emphasis on oncology. The market is growing rapidly—probably the most aggressive growth rate that we see in the pharmaceutical ...

Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC The extended relationship builds ...

This panel will present a focused playbook for biopharma patent practitioners allowing them to protect the full scope of innovation reflected in the biologic development process. The discussion will ...